



NEWS RELEASE

NEW DATA SHOWS STELARA® (USTEKINUMAB) MAINTAINED CLINICAL RESPONSE AND REMISSION AFTER TWO YEARS OF TREATMENT IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

2/17/2017